Jump to content

OBI Pharma, Inc.

From Wikipedia, the free encyclopedia
OBI Pharma, Inc.
Native name
台灣浩鼎生技股份有限公司
Company typePublic
TWSE: 4174(TPEx)
IndustryPharmaceuticals
Founded2002
Headquarters19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan
Key people
Kung-Yee Liang (Chairman)
Websitewww.obipharma.com

OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.[1][2]

In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).[3]

History

[edit]

The company was founded by Micheal N.Chang on April 29, 2002.[4] It was formerly a subsidiary of Optimer Pharmaceuticals.

On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.

On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.

On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.

Primary Focus

[edit]

The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.[5]

References

[edit]
  1. ^ "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
  2. ^ "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
  3. ^ "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
  4. ^ "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
  5. ^ "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.